Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial
Author:
Affiliation:
1. R&D Statistics; Bayer Pharma AG; Global Development; Berlin Germany
2. Global Clinical Development; Bayer Pharma AG; Global Development; Berlin Germany
3. Global Pharmacovigilance; Bayer Pharma AG; Global Development; Berlin Germany
Funder
Bayer Pharma AG
Publisher
Wiley
Subject
Obstetrics and Gynaecology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/aogs.13105/fullpdf
Reference30 articles.
1. Endometriosis: pathogenesis and treatment;Vercellini;Nat Rev Endocrinol,2014
2. ESHRE guideline: management of women with endometriosis;Dunselman;Hum Reprod,2014
3. Consensus on current management of endometriosis;Johnson;Hum Reprod,2013
4. On-label and off-label drug use in the treatment of endometriosis;Quaas;Fertil Steril,2015
5. Female perspectives on endometriosis: findings from the uterine bleeding and pain women's research study;Bernuit;J Endometr Pelvic Pain Disord,2011
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action;Pain;2024-07-02
2. CC Chemokine Family Members’ Modulation as a Novel Approach for Treating Central Nervous System and Peripheral Nervous System Injury—A Review of Clinical and Experimental Findings;International Journal of Molecular Sciences;2024-03-28
3. CCR1 mediates Müller cell activation and photoreceptor cell death in macular and retinal degeneration;eLife;2023-10-30
4. Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain;Molecules;2023-07-30
5. Substituting a randomised placebo control group with a historical placebo control in an endometriosis pain trial: a case study re-evaluating trial data using historical control data from another trial;BMJ Open;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3